NutriStack
Chromium and Linagliptin, a caution.
Linagliptin is a DPP-4 inhibitor that lowers blood glucose by prolonging endogenous GLP-1 activity. Chromium improves insulin sensitivity. On linagliptin alone the hypoglycemia risk is low, but additive effects matter when chromium is added on top of insulin or a sulfonylurea.
One pair, every claim cited. The two substances, the type, the mechanism, the recommendation, and the primary literature.
Same shape as the other 1,729 pairs in the public database.
From the interaction database
What the row says.
Every entry follows the same shape: what is happening, the mechanism, the recommendation, and the primary literature.
At a glance
- Substances
- Chromium and Linagliptin
- Pair type
- Caution
- Evidence (highest tier)
- Emerging
- Source citations
- 2 sources
- Stack Score effect
- −5 to your Stack Score (per scored caution row).
- Scope
- Supplement × Prescription
- Last verified
- May 30, 2026
Caution · Emerging evidence
Caution
What is happening. Linagliptin is a DPP-4 inhibitor that lowers blood glucose by prolonging endogenous GLP-1 activity. Chromium improves insulin sensitivity. On linagliptin alone the hypoglycemia risk is low, but additive effects matter when chromium is added on top of insulin or a sulfonylurea.
Mechanism. Linagliptin inhibits DPP-4, preserving active GLP-1 and GIP, which augments glucose-dependent insulin release. Chromium enhances insulin receptor signaling in skeletal muscle. The two mechanisms are complementary and additive.
Recommendation. If linagliptin is your only diabetes medication, chromium can be added with home glucose monitoring for the first 2-4 weeks. If you also take insulin or a sulfonylurea, ask your prescriber whether those agents need to be reduced first.
Sources (2)
- Singer GM, Geohas J. The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther. 2006;8(6):636-43. PMID 17109595
- Wong CKH, Man KKC, Shi M, et al. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy. PLoS Med. 2019;16(12):e1002999. PMID 31877127
Stack Score
How this pair moves the number.
Effect on the composite score
If both Chromium and Linagliptin are in the same stack, this pair applies −5 to your Stack Score (per scored caution row).
The full algorithm, the clamping rules, and four worked stacks are documented at /methodology/stack-score.
Check your full routine
One pair was the worked example. NutriStack runs every pair in your stack at once.
Drop in your supplements and prescriptions and the public database surfaces every interaction, synergy, timing rule, and contraindication, every one linked to its primary source.